Patents Assigned to Sugen, Inc.
  • GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF
    Publication number: 20110159532
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Application
    Filed: November 30, 2010
    Publication date: June 30, 2011
    Applicant: SUGEN, INC.
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
  • GEF-H1b: biomarkers, complexes, assays and therapeutic uses thereof
    Patent number: 7871786
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: January 18, 2011
    Assignee: Sugen, Inc.
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
  • 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
    Patent number: 7582756
    Abstract: The present invention provides a method to make a pyrrole substituted 2-indolinone compound of the formula
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: September 1, 2009
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu Jin, Paul M. Herrinton, Michael A. Mauragis
  • Pyrrole substituted 2-indolinone protein kinase inhibitors
    Patent number: 7572924
    Abstract: The present invention relates to pyrrole substituted-2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: August 11, 2009
    Assignees: Sugen, Inc., Pharmacia & Upjohn Co.
    Inventors: Peng Cho Tang, Todd Anthony Miller, Xiaoyuan Li, Connie Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof
    Patent number: 7439329
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: October 21, 2008
    Assignee: Sugen, Inc.
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
  • Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer
    Patent number: 7320996
    Abstract: The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors of the formula I: wherein R1, R2, R3, R4, R5, R6, and R7 are defined herein, in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: January 22, 2008
    Assignees: Sugen, Inc, Pharmacia Corporation
    Inventors: Jaime Masferrer, Parul Doshi, Julie Cherrington
  • 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors
    Patent number: 7256189
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: August 14, 2007
    Assignees: Sugen, Inc., Pharmacia & Upjohn Company
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu (Alan) Jin, Paul M. Herrinton, Michael A. Mauragis
  • Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
    Patent number: 7250417
    Abstract: The present invention relates to compounds of the Formulae (I)-(IV), wherein R1-R6, R11-R13, X and Y are defined herein, and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: July 31, 2007
    Assignee: Sugen Inc.
    Inventors: Jingrong Cui, Iriny Botrous
  • Aminoheteroaryl compounds as protein kinase inhibitors
    Patent number: 7230098
    Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: June 12, 2007
    Assignee: Sugen, Inc.
    Inventors: Jingrong Jean Cui, Dilip Bhumralkar, Iriny Botrous, Ji Yu Chu, Lee A. Funk, Cathleen Elizabeth Hanau, G. Davis Harris, Lei Jia, Joanne Johnson, Stephen A. Kolodziej, Pei-Pei Kung, Xiaoyuan (Sharon) Li, Jason (Qishen) Lin, Jerry Jialun Meng, Mitchell David Nambu, Christopher G. Nelson, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube, Allison Walter, Fang-Jie Zhang, Jennifer Zhang
  • Method and compositions for inhibiting cell proliferative disorders
    Patent number: 7217737
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity HER2 or EGFR.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: May 15, 2007
    Assignees: Yissum Research and Development Company of the Hebrew University of Jerusalem, Sugen, Inc.
    Inventors: Hui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Peng Cho Tang, Laura K. Shawver, Jianming Tsai
  • (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors
    Patent number: 7214700
    Abstract: The present invention relates to (2-oxindol-3-ylidenyl)acetic acid derivatives which modulate the activity of protein kinases and are therefore useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: May 8, 2007
    Assignee: Sugen Inc.
    Inventors: Chung Chen Wei, Peng Cho Tang
  • Methods of modulating tyrosine protein kinase function with indolinone compounds
    Patent number: 7211600
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: May 1, 2007
    Assignee: Sugen Inc.
    Inventors: Ken Lipson, Gerald McMahon
  • Indolinone combinatorial libraries and related products and methods for the treatment of disease
    Patent number: 7202265
    Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1? position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: April 10, 2007
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Connie Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • Bicyclic protein kinase inhibitors
    Patent number: 7189721
    Abstract: The present invention relates to novel 3-hetero-arylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: March 13, 2007
    Assignee: Sugen Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
    Patent number: 7186832
    Abstract: The present invention relates to substituted imidazopyrazines of the general Formula I which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 6, 2007
    Assignee: Sugen Inc.
    Inventors: Connie Li Sun, Congxin Liang, Ping Huang, G. Davis Harris, Jr., Huiping Guan
  • 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
    Patent number: 7186716
    Abstract: Compounds of Formula I are useful as mediators of protein kinases and have activity as cell proliferation inhibitors: where X, R1–R7 and R9 are as defined herein.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: March 6, 2007
    Assignee: Sugen, Inc.
    Inventors: Chung Chen Wei, Ping Huang, Yi Xia
  • Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
    Patent number: 7157460
    Abstract: The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: January 2, 2007
    Assignee: Sugen Inc.
    Inventors: Connie Li Sun, Congxin Liang, Ping Huang, G. Davis Harris, Jr., Huiping Guan
  • 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
    Patent number: 7157577
    Abstract: The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: January 2, 2007
    Assignee: Sugen Inc.
    Inventors: Peng Cho Tang, Congxin Liang, Todd Miller, Kenneth E. Lipson
  • Triazolotriazine compounds and uses thereof
    Patent number: 7122548
    Abstract: The present invention relates to compounds of the Formula (I), and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: October 17, 2006
    Assignee: Sugen, Inc.
    Inventors: Fang-Jie Zhang, Tomas Vojkovsky, Ping Huang, Congxin Liang, Steven Huy Do, Marcel Koenig, Jingrong Cui
  • Diagnosis and treatment of AUR1 and/or AUR2 related disorders
    Patent number: 7119174
    Abstract: The present invention relates to AUR1 and/or AUR2 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for AUR1 and/or AUR2 related diseases or conditions characterized by an abnormal interaction between a AUR1 and/or AUR2 polypeptide and a AUR1 and/or AUR2 binding partner.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: October 10, 2006
    Assignee: Sugen, Inc.
    Inventors: Gregory Plowman, James Bishoff